Management for phenylketonuria (PKU) has traditionally involved adhering to a strict low-protein diet to maintain phenylalanine (Phe) levels within the recommended range (μmol/L). The time commitment and financial, emotional, and social burdens of adhering to a restrictive diet, as well as the neurocognitive symptoms associated with elevated Phe levels, make it challenging to manage PKU and lead to reductions in quality of life. Palynziq® is an enzyme substitution therapy used to lower blood Phe levels and liberate individuals with PKU from their restrictive diets. Previous studies have demonstrated the safety and efficacy of Palynziq®, but our study is the first to our knowledge to investigate the subjective impact of Palynziq® on quality of life. We surveyed 34 individuals currently treated with Palynziq® about its impact on four domains of quality of life: neurocognitive, emotional/psychiatric, social, and practical. There was a statistically significant improvement in every symptom and impact on quality of life addressed by this study after responding to Palynziq® (p < 0.05). The greatest improvements were in guilt and stress about diet and Phe levels; difficulty with planning/organization and concentration/attention; difficulty and inconvenience of diet adherence; and diet satisfaction. The majority of participants agreed or strongly agreed that Palynziq® made daily life easier and that it improved their cognitive functioning, emotional wellbeing, physical health, and social interactions. For nearly every impact on quality of life, there were no significant differences in improvement based on average Phe levels pre-Palynziq®, indicating that Palynziq® may be beneficial regardless of initial Phe levels. Quality of life aspects that remained significant challenges post-Palynziq® included the financial burden and difficulty with insurance, feeling different or isolated from others, difficulty traveling, and strain in relationships with friends and family. The results of this study indicate that Palynziq® has an overwhelmingly positive impact on quality of life overall. However, there remain social and financial challenges which should be targets for support of this patient population and may be addressed by interventions such as the involvement of social workers, counselors, and psychologists in their care, as well as increased awareness of and access to financial assistance programs.
","abstract_html":"<p>Management for phenylketonuria (PKU) has traditionally involved adhering to a strict low-protein diet to maintain phenylalanine (Phe) levels within the recommended range (μmol/L). The time commitment and financial, emotional, and social burdens of adhering to a restrictive diet, as well as the neurocognitive symptoms associated with elevated Phe levels, make it challenging to manage PKU and lead to reductions in quality of life. Palynziq<sup>®</sup> is an enzyme substitution therapy used to lower blood Phe levels and liberate individuals with PKU from their restrictive diets. Previous studies have demonstrated the safety and efficacy of Palynziq<sup>®</sup>, but our study is the first to our knowledge to investigate the subjective impact of Palynziq<sup>®</sup> on quality of life. We surveyed 34 individuals currently treated with Palynziq<sup>®</sup> about its impact on four domains of quality of life: neurocognitive, emotional/psychiatric, social, and practical. There was a statistically significant improvement in every symptom and impact on quality of life addressed by this study after responding to Palynziq<sup>®</sup> (p < 0.05). The greatest improvements were in guilt and stress about diet and Phe levels; difficulty with planning/organization and concentration/attention; difficulty and inconvenience of diet adherence; and diet satisfaction. The majority of participants agreed or strongly agreed that Palynziq<sup>®</sup> made daily life easier and that it improved their cognitive functioning, emotional wellbeing, physical health, and social interactions. For nearly every impact on quality of life, there were no significant differences in improvement based on average Phe levels pre-Palynziq<sup>®</sup>, indicating that Palynziq<sup>®</sup> may be beneficial regardless of initial Phe levels. Quality of life aspects that remained significant challenges post-Palynziq<sup>®</sup> included the financial burden and difficulty with insurance, feeling different or isolated from others, difficulty traveling, and strain in relationships with friends and family. The results of this study indicate that Palynziq<sup>®</sup> has an overwhelmingly positive impact on quality of life overall. However, there remain social and financial challenges which should be targets for support of this patient population and may be addressed by interventions such as the involvement of social workers, counselors, and psychologists in their care, as well as increased awareness of and access to financial assistance programs.</p>","abstract_has_math":false,"creators":["Heller, Teresa","0000-0002-5139-4770
"],"institution":null,"degree_name":"Masters of Science (MS)","degree_level":"Thesis (MS)","degree_discipline":null,"degree_department":null,"school":null,"contributors":["Kate Richardson, M.S., CGC","Syed Hashmi, M.D., M.P.H., Ph.D.","Hope Northrup, M.D., FACMG"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2023,"date_issued":"2023-05-01T07:00:00Z","date_published":"2023-05-01T07:00:00Z","updated_at":"2026-07-24T05:49:41Z","subjects":["phenylketonuria","PKU","Palynziq","pegvaliase","enzyme substitution therapy","quality of life","QoL","Enzymes and Coenzymes","Medical Genetics","Nutritional and Metabolic Diseases"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"https://digitalcommons.library.tmc.edu/utgsbs_dissertations/1270","outbound_label":"Repository record","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Kate Richardson, M.S., CGC","Syed Hashmi, M.D., M.P.H., Ph.D.","Hope Northrup, M.D., FACMG"]},{"key":"dc:creator","label":"Author","values":["Heller, Teresa","0000-0002-5139-4770
"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.available","label":"Dc Date Available","values":["2025-04-25T07:00:00Z"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Thesis (MS)"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Masters of Science (MS)"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["phenylketonuria","PKU","Palynziq","pegvaliase","enzyme substitution therapy","quality of life","QoL","Enzymes and Coenzymes","Medical Genetics","Nutritional and Metabolic Diseases"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://digitalcommons.library.tmc.edu/utgsbs_dissertations/1270"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Management for phenylketonuria (PKU) has traditionally involved adhering to a strict low-protein diet to maintain phenylalanine (Phe) levels within the recommended range (μmol/L). The time commitment and financial, emotional, and social burdens of adhering to a restrictive diet, as well as the neurocognitive symptoms associated with elevated Phe levels, make it challenging to manage PKU and lead to reductions in quality of life. Palynziq® is an enzyme substitution therapy used to lower blood Phe levels and liberate individuals with PKU from their restrictive diets. Previous studies have demonstrated the safety and efficacy of Palynziq®, but our study is the first to our knowledge to investigate the subjective impact of Palynziq® on quality of life. We surveyed 34 individuals currently treated with Palynziq® about its impact on four domains of quality of life: neurocognitive, emotional/psychiatric, social, and practical. There was a statistically significant improvement in every symptom and impact on quality of life addressed by this study after responding to Palynziq® (p < 0.05). The greatest improvements were in guilt and stress about diet and Phe levels; difficulty with planning/organization and concentration/attention; difficulty and inconvenience of diet adherence; and diet satisfaction. The majority of participants agreed or strongly agreed that Palynziq® made daily life easier and that it improved their cognitive functioning, emotional wellbeing, physical health, and social interactions. For nearly every impact on quality of life, there were no significant differences in improvement based on average Phe levels pre-Palynziq®, indicating that Palynziq® may be beneficial regardless of initial Phe levels. Quality of life aspects that remained significant challenges post-Palynziq® included the financial burden and difficulty with insurance, feeling different or isolated from others, difficulty traveling, and strain in relationships with friends and family. The results of this study indicate that Palynziq® has an overwhelmingly positive impact on quality of life overall. However, there remain social and financial challenges which should be targets for support of this patient population and may be addressed by interventions such as the involvement of social workers, counselors, and psychologists in their care, as well as increased awareness of and access to financial assistance programs.
"]},{"key":"dc:title","label":"Title","values":["The Impact of Treatment With Palynziq® On Quality of Life For Individuals With Pku"]}]}],"canonical_facts":{"dc:contributor":["Kate Richardson, M.S., CGC","Syed Hashmi, M.D., M.P.H., Ph.D.","Hope Northrup, M.D., FACMG"],"dc:creator":["Heller, Teresa","0000-0002-5139-4770
"],"dc:date.available":["2025-04-25T07:00:00Z"],"dc:description.abstract":["Management for phenylketonuria (PKU) has traditionally involved adhering to a strict low-protein diet to maintain phenylalanine (Phe) levels within the recommended range (μmol/L). The time commitment and financial, emotional, and social burdens of adhering to a restrictive diet, as well as the neurocognitive symptoms associated with elevated Phe levels, make it challenging to manage PKU and lead to reductions in quality of life. Palynziq® is an enzyme substitution therapy used to lower blood Phe levels and liberate individuals with PKU from their restrictive diets. Previous studies have demonstrated the safety and efficacy of Palynziq®, but our study is the first to our knowledge to investigate the subjective impact of Palynziq® on quality of life. We surveyed 34 individuals currently treated with Palynziq® about its impact on four domains of quality of life: neurocognitive, emotional/psychiatric, social, and practical. There was a statistically significant improvement in every symptom and impact on quality of life addressed by this study after responding to Palynziq® (p < 0.05). The greatest improvements were in guilt and stress about diet and Phe levels; difficulty with planning/organization and concentration/attention; difficulty and inconvenience of diet adherence; and diet satisfaction. The majority of participants agreed or strongly agreed that Palynziq® made daily life easier and that it improved their cognitive functioning, emotional wellbeing, physical health, and social interactions. For nearly every impact on quality of life, there were no significant differences in improvement based on average Phe levels pre-Palynziq®, indicating that Palynziq® may be beneficial regardless of initial Phe levels. Quality of life aspects that remained significant challenges post-Palynziq® included the financial burden and difficulty with insurance, feeling different or isolated from others, difficulty traveling, and strain in relationships with friends and family. The results of this study indicate that Palynziq® has an overwhelmingly positive impact on quality of life overall. However, there remain social and financial challenges which should be targets for support of this patient population and may be addressed by interventions such as the involvement of social workers, counselors, and psychologists in their care, as well as increased awareness of and access to financial assistance programs.
"],"dc:identifier":["https://digitalcommons.library.tmc.edu/utgsbs_dissertations/1270"],"dc:subject":["phenylketonuria","PKU","Palynziq","pegvaliase","enzyme substitution therapy","quality of life","QoL","Enzymes and Coenzymes","Medical Genetics","Nutritional and Metabolic Diseases"],"dc:title":["The Impact of Treatment With Palynziq® On Quality of Life For Individuals With Pku"],"thesis:degree_level":["Thesis (MS)"],"thesis:degree_name":["Masters of Science (MS)"]},"updated_at":"2026-07-24T05:49:41Z"}